课题基金 / 基金详情

NMR Spectral Markers of Cartilage Degeneration in Osteoarthritis

NMR Spectral Markers of Cartilage Degeneration in Osteoarthritis
骨关节炎软骨退变的核磁共振谱标记
批准号:
7738537
负责人:
Xiaojuan Li
金额:
$20.86万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2011-07-31

项目摘要

项目成果

Xiaojuan Li的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Osteoarthritis (OA) is a major health concern with very limited treatment options. Understanding biochemical and molecular changes in OA cartilage can provide clues for new therapeutic targets. Furthermore, there is clearly a need for in vivo imaging techniques that can non-invasively and critically evaluate the therapeutic efficacy of new treatment methods. Magnetic resonance imaging (MRI) has been used to study cartilage degeneration by observing the changes in water content, relaxation and diffusion. However, these changes are indirect by-products of alterations in proteoglycan (PG)/collagen matrix in degenerative cartilage, and do not provide direct measures of biochemical changes. This is the gap our research is intended to fill. High Resolution - Magic Angle Spinning (HRMAS) spectroscopy is a unique non-destructive ex vivo technique that can provide direct measurement of biochemical changes in tissues. However, studies using HRMAS in human cartilage are very limited and no relationship between biochemical changes measured by HRMAS and cartilage degeneration has been established. Our long-term goal is to develop non-invasive imaging markers for early degeneration of cartilage. The goal of this proposal is to develop and validate ex vivo HRMAS techniques for evaluating biochemical changes in cartilage matrix associated with OA. The central hypothesis is that the non-destructive imaging capability of HRMAS will lead to identification of spectroscopic markers of early cartilage degeneration that can be related to the molecular changes in osteoarthritic cartilage matrix such as PG/collagen degradation. This research is an essential first step in the development of a novel, in vivo, non-invasive diagnostic tool that provides direct measurement of cartilage biochemistry for early OA. Specifically, we will 1) establish and optimize HRMAS acquisition protocols in human cartilage; 2) identify biochemical changes associated with cartilage degeneration using HRMAS. Cartilage samples will be harvested from OA patients who undergo total knee replacement and cadaver knees (controls). Cartilage degeneration will be evaluated using histology. HRMAS measurement between control and OA samples will be compared and HRMAS spectral markers for cartilage degeneration will be identified. HRMAS measurement will be correlated with PG and collagen assay quantitation as well as with immnohistochemical analysis on aggrecan and collagen cleavage neoepitopes. This project is novel in developing and applying ex vivo HRMAS techniques to characterize biochemical changes in human OA cartilage. The future extension of this to in vivo MR spectroscopy is what makes this study clinically significant and exciting. PUBLIC HEALTH RELEVANCE: Osteoarthritis (OA) affects more than 25 million Americans and is one of the leading causes of disability. Current treatment to OA is very limited and diagnosis of early cartilage degeneration remains a challenge. This proposal aims at developing a novel ex vivo NMR method to explore spectral markers for cartilage degeneration in OA. This research is an essential first step in the development of a novel, non-invasive, diagnostic tool that provides direct measurement of cartilage biochemistry for early OA, which will significantly improve patient management and clinical care of OA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
  • 批准号:
    10861563
  • 项目类别:
  • 资助金额:
    $30.59万
  • 财政年份:
    2023
  • 负责人:
    Xiaojuan Li
  • 依托单位:
Novel causal inference methods to inform clinical decision on when to discontinue symptomatic treatment for patients with dementia
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: